NIFTY  8,896.70  -0.48%
  SENSEX  28,812.90  -0.28%
 CURRENCY  Rs  66.83/$ 70.65/€, 83.79/£
  GOLD  29,592.00  -0.10%
  SILVER  43,342.00  -0.03%
  DAX  11,804.00  -1.20%
  FTSE  7,243.70  -0.38%
  CAC  4,845.24  -0.79%
  HANG SENG  23,925.10  -0.17%
  NIKKEI  19,107.50  -0.91%
  Shanghai Composite  3,228.66  -0.42%
  DOW JONES  20,821.80  0.06%
  NASDAQ  5,845.31  0.17%
  S&P 500  2,367.34  0.15%
SANOFI INDIA Q4 - Net Sales At Rs 552 Cr Vs Rs 522 Cr YoY SANOFI INDIA Q4 - Net Profit At Rs 50.5 Cr Vs Rs 120 Cr YoY

Ranbaxy Q4: Co Allays U.S. FDA Fears

Video:

Play this video

February 5: Ranbaxy's fourth quarter revenues and margins have come in-line with street estimates. Also, commentary from the management on the U.S. FDA ban at Toansa has boosted the stock. The management allayed fears regarding the U.S. FDA ban on their Toansa facility. Agam Vakil and Priya Sheth share more details on the company’s Q4 results and the management commentary.